UPDATED LIFETIME SURVIVAL ESTIMATES FOR NIVOLUMAB plus IPILIMUMAB IN PREVIOUSLY UNTREATED ADVANCED/METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA (1L ARCC)

被引：0
|
作者：
Qendri, V [1 ]
May, J. [2 ]
Malcolm, B. [2 ]
Ejzykowicz, F. [3 ]
Kurt, M. [3 ]
Cakar, E. [1 ]
Klijn, S. [1 ]
机构：
[1] Pharmerit, Rotterdam, Netherlands
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG5
引用
收藏
页码：S520 / S520
页数：1
相关论文
共 50 条
  • [21] Characterization of response to nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214
    Rini, B. I.
    Tannir, N. M.
    Escudier, B.
    McDermott, D. F.
    Grimm, M-O.
    Porta, C.
    Powles, T.
    Kollmannsberger, C. K.
    Gurney, H. P.
    Tykodi, S. S.
    Harrison, M.
    Heng, D. Y. C.
    Gruenwald, V.
    Choueiri, T. K.
    Mekan, S.
    McHenry, M. B.
    Hammers, H. J.
    Motzer, R. J.
    George, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma
    Ambavane, Apoorva
    Yang, Shuo
    Atkins, Michael B.
    Rao, Sumati
    Shah, Anshul
    Regan, Meredith M.
    McDermott, David F.
    Michaelson, M. Dror
    IMMUNOTHERAPY, 2020, 12 (01) : 37 - 51
  • [23] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE
    Branchoux, S.
    Negrier, S.
    de Peretti, C.
    Malcolm, B.
    May, J.
    Marie, L.
    Gaudin, A. F.
    Klijn, S.
    Ignacio, T. J.
    VALUE IN HEALTH, 2019, 22 : S477 - S477
  • [24] A PHASE 3 STUDY (COSMIC-313) OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB AND IPILIMUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA OF INTERMEDIATE OR POOR RISK
    Choueiri, Toni
    Albiges, Laurence
    Powles, Thomas
    Mohamed, Nehal
    Wang, Fong
    Motzer, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A209 - A209
  • [25] ESTIMATING LONG-TERM SURVIVORSHIP RATES FOR PREVIOUSLY UNTREATED INTERMEDIATE OR POOR (I/P) RISK ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI): ANALYSES FROM THE CHECKMATE 214 TRIAL
    Paly, V
    George, S.
    Youn, J. H.
    Borrill, J.
    Ejzykowicz, F.
    May, J. R.
    Kurt, M.
    VALUE IN HEALTH, 2022, 25 (01) : S210 - S210
  • [26] Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective
    Engel Ayer Botrel, Tobias
    Datz Abadi, Marcia
    Chabrol Haas, Laura
    da Veiga, Cassia Rita Pereira
    de Vasconcelos Ferreira, Dominihemberg
    Jardim, Denis Leonardo
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 291 - 298
  • [27] Prognostic factors for Overall Survival (OS) in patients receiving First-line (1L) Nivolumab plus Ipilimumab (NIVO plus IPI) for advanced/metastatic Renal Cell Carcinoma (aRCC) in a real-world setting in Germany
    Bedke, J.
    Gruenwald, V.
    Mueller-Huesmann, H.
    Belz, H.
    Von Der Heyde, E.
    Boegemann, M.
    Strauss, A.
    Vaz, L.
    Bluhmki, T.
    Herber, M.
    Groetzinger, S.
    Grimm, M-O.
    EUROPEAN UROLOGY, 2024, 85 : S1844 - S1845
  • [28] A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk.
    Choueiri, Toni K.
    Albiges, Laurence
    Powles, Thomas
    Scheffold, Christian
    Wang, Fong
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] INVESTIGATING TIME TO NEXT TREATMENT AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PREVIOUSLY UNTREATED INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA PATIENTS: AN INSIGHT FROM THE PHASE III CHECKMATE-214
    Branchoux, S.
    Sofeu, C. L.
    Kurt, M.
    Gaudin, A. F.
    Italiano, A.
    Rondeau, V
    Bellera, C.
    VALUE IN HEALTH, 2020, 23 : S402 - S402
  • [30] THE IMPACT OF CLINICAL HETEROGENEITY ON CONDUCTING NETWORK META-ANALYSES FOR OVERALL SURVIVAL IN PREVIOUSLY UNTREATED INTERMEDIATE-OR POOR-RISK ADVANCED/METASTATIC RENAL CELL THERAPIES
    Szabo, N.
    Grevinga, M.
    Kurt, M.
    Ejzykowicz, F.
    Chun, D. S.
    Malcolm, B.
    Kroep, S.
    May, J.
    VALUE IN HEALTH, 2020, 23 : S750 - S750
12345